TrialCirculation2018

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Kenneth W Mahaffey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.